BellaSeno Appoints Dr. Mohit Chhaya as Chief Executive Officer

Dr. Mohit Chhaya is an internationally renowned expert in biomedical engineering and additive manufacturing and has played a key role in the development of BellaSeno’s technology platform. In his role as CTO, Dr. Chhaya led the growth and development of Bellaseno and the Company´s additive manufacturing processes from initial conception to full ISO 13485 certification. Dr. Chhaya’s PhD thesis, for which he received a university-wide Best Thesis Award in 2015, was focused on the design and manufacturing of the novel breast implants used by BellaSeno.

Prior to BellaSeno, Dr. Chhaya worked as a post-doctoral researcher at Technical University of Munich (TUM) – where he shaped the global regulatory strategy for innovative scaffolds for lymph-node regeneration. Prior to his PhD, Dr. Chhaya worked as a data analyst at Moody’s Analytics for 2.5 years.

Mohit Chhaya is an author of several patents and a number of peer-reviewed academic publications in top-tier journals.

“I would like to thank Simon Champ for significantly contributing to advancing BellaSeno from a start-up to a promising, ISO-certified regenerative medicine company,” said Mohit Chhaya, Chief Executive Officer of BellaSeno. “Simon has played an important role in founding and growing BellaSeno to a recognized industry player and we are glad that he will join BellaSeno´s Supervisory Board.”

"Simon Champ has been an invaluable part of BellaSeno´s founding team and I also thank him for his impressive achievements over the past years," said Herbert Stadler, co-founder and board member of BellaSeno. "We are delighted that Mohit Chhaya has agreed to take over the role as BellaSeno´s CEO, thereby ensuring a smooth transition and the sustained execution of our corporate strategy. We are now looking forward to reaching further milestones in 2020, in particular the first clinical study of Senella. Moreover, we will extend our product pipeline to include additional soft tissue reconstruction applications."